Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

ClinicalTrials.gov ID: NCT02228681

Public ClinicalTrials.gov record NCT02228681. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/Medroxyprogesterone Acetate) in Women With Advanced, Recurrent, or Persistent Endometria Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to evaluate the effectiveness of the combination of the drugs Everolimus and Letrozole compared to Tamoxifen and Medroxyprogesterone acetate in treating endometrial cancer and to determine the types and severity of side effects caused by treatment with these drug combinations.

Study identification

NCT ID
NCT02228681
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GOG Foundation
Network
Enrollment
74 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 20, 2015
Primary completion
Dec 31, 2017
Completion
Aug 21, 2024
Last update posted
Sep 18, 2024

2015 – 2024

United States locations

U.S. sites
26
U.S. states
19
U.S. cities
24
Facility City State ZIP Site status
University of Colorado - Anschutz Cancer Pavilion Aurora Colorado 80045
University of Miami - Sylvester Comprehensive Cancer Center Miami Florida 33136
John B. Amos Cancer Center Columbus Georgia 31904
Memorial Health University Medical Center Savannah Georgia 31404
Maine Medical Center Scarborough Maine 04074
Johns Hopkins Baltimore Maryland 21287
University of Massachusetts Memorial Center Worcester Massachusetts 01605
Sanford Clinic North - Bemidji Bemidji Minnesota 56601
St. Dominic-Jackson Memorial Hospital Jackson Mississippi 39215
University of Mississippi Medical Center Jackson Mississippi 39216
Women's Cancer Center of Nevada Las Vegas Nevada 89169
New Mexico Cancer Alliance Albuquerque New Mexico 87106
Memorial Medical Center-Cancer Center Albuquerque New Mexico 87131
Women's Cancer Care Associates Albany New York 12208
SUNY Downstate Medical Center Brooklyn New York 11203
Sanford Roger Maris Cancer Center Fargo North Dakota 58122
University Hospital Case Medical Center Cleveland Ohio 44106
Ohio State University Columbus Ohio 43210
University of Oklahoma Oklahoma City Oklahoma 73104
Abington Memorial Hospital Abington Pennsylvania 19001-3788
The University of Pennsylvania Philadelphia Pennsylvania 19104
Magee Women's Hospital of UPMC Pittsburgh Pennsylvania 15213
Women & Infants Hospital of Rhode Island Providence Rhode Island 02905
Sanford Medical Center - Sioux Falls Sioux Falls South Dakota 57104
University of Texas MD Anderson Cancer Center Houston Texas 77030
Huntsman Cancer Institute Salt Lake City Utah 84112

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02228681, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 18, 2024 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02228681 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →